Author: Akhmetova Aigerim
Editor: Merentsova Anastasia
Sepsis is an inflammatory reaction in response to the generalization of a local infectious process, a complication of a wound or inflammatory process. Its causative agents are most often streptococci and staphylococci, less often pneumococci, Escherichia coli, Pseudomonas aeruginosa, Salmonella, meningococcus, gonococcus, etc.
Despite the fact that the pharmaceutical industry provides us with a wide range of antibiotics for sepsis, the emergence of bacterial resistance (resistance) requires constant adjustments in drug therapy and the development of the most effective drugs.
One of the most promising innovations in the field of pharmacy in intensive care is the use of monoclonal antibodies, which can be produced in response to the introduction of almost any natural antigen (mainly proteins and polysaccharides) that the antibody will specifically bind. Monoclonal antibodies are antibodies produced by immune cells belonging to the same cell clone. One of these variants of antibodies is - an antibody against Staphylococcus aureus - suvratoxumab.
Suvratoxumab is a human protein that binds to Staphylococcus aureus antigens and effectively blocks it. According to the study, a single intravenous dose of suvratoxumab led to a decrease in the incidence of pneumonia caused by staphylococcus in patients with this pathology. The same mechanism of action of antibodies against Pseudomonas aeruginosa.
According to scientists, the use of this method can provide invaluable service not only in leveling the symptoms of the underlying disease, but also of its complications. The authors of the work are confident that in the near future a wide variety of medical interventions will be offered in a timely manner, depending on the phenotype (subspecies) of septic patients.
Source: https://pubmed.ncbi.nlm.nih.gov/32951149/
